CYTOO

Executive Summary

CYTOO is a French biotechnology company founded in 2005 and headquartered in Grenoble, specializing in muscle pathology research and drug discovery. The company’s core asset is its proprietary MyoScreen™ platform, which uses micropatterning technology to create standardized, physiologically relevant human muscle cell models. These models enable more accurate screening of therapeutic candidates, reducing reliance on animal testing and accelerating the development of treatments for muscle diseases. CYTOO operates at the intersection of cell therapy and drug delivery, offering both services and products to pharmaceutical and biotechnology partners. By providing high-throughput, reproducible assays, the company addresses a critical bottleneck in neuromuscular drug development, particularly for conditions such as Duchenne muscular dystrophy, sarcopenia, and cachexia. CYTOO’s platform uniquely captures human muscle biology in a format compatible with industrial-scale screening, positioning it as a key enabler for muscle-targeted therapies. The company’s business model combines revenue from service contracts and licensing, with potential for future product-based growth as its technology is adopted across the industry. With a strong intellectual property portfolio and a focus on unmet medical needs, CYTOO is well-positioned to capture value in the growing precision medicine and muscle research markets.

Upcoming Catalysts (preview)

• Q2 2026New pharmaceutical partnership for MyoScreen platform60% success
• Q4 2026Series B funding round to expand commercial operations50% success
• Q1 2027Launch of next-generation high-throughput screening service40% success